Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.

Literature DB >> 22743624

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.

S Ettou, E Audureau, C Humbrecht, B Benet, H Jammes, T Clozel, V Bardet, C Lacombe, F Dreyfus, P Mayeux, E Solary, M Fontenay.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2012 PMID： 22743624 DOI： 10.1038/leu.2012.152

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

Review 1. Predicting response to epigenetic therapy.

Authors: Marianne B Treppendahl; Lasse S Kristensen; Kirsten Grønbæk
Journal: J Clin Invest Date: 2014-01-02 Impact factor: 14.808

Review 2. Epigenetic alterations in osteosarcoma: promising targets.

Authors: Binghao Li; Zhaoming Ye
Journal: Mol Biol Rep Date: 2014-02-06 Impact factor: 2.316

Review 3. Epigenetics of myelodysplastic syndromes.

Authors: R Itzykson; P Fenaux
Journal: Leukemia Date: 2013-11-19 Impact factor: 11.528

4. Cigarette Smoking and the Risk of Adult Myeloid Disease: A Meta-Analysis.

Authors: Peng Wang; Huifang Liu; Ting Jiang; Julun Yang
Journal: PLoS One Date: 2015-09-04 Impact factor: 3.240

5. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Authors: J M Bogenberger; S M Kornblau; W E Pierceall; R Lena; D Chow; C-X Shi; J Mantei; G Ahmann; I M Gonzales; A Choudhary; R Valdez; J Camoriano; V Fauble; R E Tiedemann; Y H Qiu; K R Coombes; M Cardone; E Braggio; H Yin; D O Azorsa; R A Mesa; A K Stewart; R Tibes
Journal: Leukemia Date: 2014-01-23 Impact factor: 11.528

6. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Authors: Anna Raimbault; Cecile Pierre-Eugene; Alexandra Rouquette; Celine Deudon; Lise Willems; Nicolas Chapuis; Stephanie Mathis; Claudia Kunz; Harald Fricke; Olivier Kosmider; Valerie Bardet; Michaela Fontenay
Journal: Oncotarget Date: 2016-03-22

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.

Review 1. Predicting response to epigenetic therapy.

Review 2. Epigenetic alterations in osteosarcoma: promising targets.

Review 3. Epigenetics of myelodysplastic syndromes.

4. Cigarette Smoking and the Risk of Adult Myeloid Disease: A Meta-Analysis.

5. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

6. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

7. Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.

8. Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy.

9. Immunological derangement in hypocellular myelodysplastic syndromes.

10. Fas-Antisense Long Noncoding RNA and Acute Myeloid Leukemia: Is There any Relation?